SpinChip Diagnostics to be Acquired by bioMérieux

• Transaction Valuation: SpinChip valued at NOK 1,624 million (EUR 138 million), making it one of the largest MedTech transactions in Norway.
• Menu Development: bioMérieux will accelerate the menu build-up of SpinChip’s Point of Care diagnostics platform.
• Strategic Growth: bioMérieux strengthens its position in the Point of Care market.

Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million.

Morten Jurs, Chief Executive Officer of SpinChip, stated:

“The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to significantly improve healthcare outcomes for patients. Our recent collaboration with bioMérieux has been highly productive and has brought us closer to the commercialisation of the platform. I am confident that bioMérieux’s leadership will effectively utilise the platform’s potential to provide efficient and improved diagnostic solutions for patients and healthcare workers worldwide.”

Pierre Boulud, Chief Executive Officer of bioMérieux, commented:

“The acquisition of SpinChip is very promising for bioMérieux and fully consistent with our GO•28 strategic plan agenda. We already serve the point-of-care market with BIOFIRE® SPOTFIRE®, a best-in-class molecular biology system. SpinChip’s groundbreaking technology complements our offering and strengthens our presence in the Point of Care segment. This acquisition will also allow us to leverage bioMérieux’s unique R&D and manufacturing capabilities in the field of immunoassays that we have built with VIDAS®. SpinChip will pave the way for bioMérieux’s growth beyond 2028, sustaining our mission to enhance patient outcomes worldwide.”

Since its founding in 2012, SpinChip has developed a revolutionary in vitro diagnostics platform capable of rapidly conducting a wide range of tests across therapeutic areas such as cardiovascular, inflammatory/sepsis, infectious and endocrine diseases. With this, SpinChip’s technology aims to enhance diagnostic efficiency for patients and physicians while reducing healthcare costs.

The SpinChip platform currently delivers highly accurate diagnostic results for detecting Myocardial Infarction (MI), a leading cause of global morbidity and mortality. Capable of producing results comparable to state-of-the-art laboratory diagnostic machines within minutes and near the patient, the platform is particularly suited for Emergency Departments and Urgent Care Units.

SpinChip’s high-sensitive troponin MI assay has already demonstrated strong results in a retrospective clinical study (Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitvity Cardiac Troponin I Assay). The assay is now undergoing additional national and international trials, including a large multicenter European clinical study. SpinChip plans to launch the MI assay during H1 2026.

Under bioMérieux’s ownership, the platform and additional immunoassays in the area of acute care, focusing on sepsis and other cardiovascular biomarkers, will be developed.

Stig Morten Borch, Founder of SpinChip, added:

“Our vision has always been to improve diagnostic speed and accuracy, offering performance on par with central laboratory assays. With bioMérieux’s expertise, we are now on the cusp of commercialising our first test. I am immensely grateful to Sintef’s initial support and everyone who has supported our journey. I am also confident in bioMérieux’s ability to bring our innovation to market.”

Åse Aulie Michelet, Chair of SpinChip, remarked:

“This transaction reflects the cutting-edge advancements made by SpinChip. Throughout our journey, Investinor, as our anchor investor since 2016, has been an important contributor to the company’s success.  As a global leader in in vitro diagnostics, bioMérieux is the perfect partner to drive SpinChip’s platform to commercialisation and beyond.”

Carnegie Investment Bank and ABG Sundal Collier acted as financial advisors and Wiersholm as legal advisor to SpinChip and its owners in connection with the transaction.